Institutional members access full text with Ovid®

Share this article on:

Gynecomastia: An Update

Pearlman, Gwen DO*; Carlson, Harold E. MD†

doi: 10.1097/01.ten.0000205637.20746.10
CME Review Article #12

Gynecomastia is a common condition that is frequently evaluated by endocrinologists. In most cases, male breast enlargement results from an excess of stimulatory estrogenic influences over inhibitory androgenic effects on the breast. Diagnostic evaluation is directed at excluding breast malignancy and establishing the cause of the gynecomastia. Medical therapy with tamoxifen appears to be frequently effective.

*Fellow in Endocrinology, Diabetes and Metabolism, Stony Brook University; and †Professor of Medicine, Division Head, Endocrinology & Metabolism, Department of Medicine, Stony Brook University, Stony Brook, New York.

The authors have disclosed that this article discusses unlabeled/investigational uses of danazol, tamoxifen, raloxifene, and anastrazole.

The authors have disclosed that they have no significant relationships with or financial interests in any commercial company that pertains to this educational activity.

Wolters Kluwer Health has identified and resolved all faculty conflicts of interest regarding this educational activity.

Reprints: Harold E. Carlson, MD, Endocrinology Division, Department of Medicine, HSC T15-060, Stony Brook University, Stony Brook, NY 11794-8154. E-mail: harold.carlson@stonybrook.edu

Chief Editor's Note: This article is the 12th of 36 that will be published in 2006 for which a total of up to 36 Category 1 CME credits can be earned. Instructions for how credits can be earned precede the CME Examination at the back of this issue.

© 2006 Lippincott Williams & Wilkins, Inc.